论文部分内容阅读
目的:比较唑来膦酸与伊班膦酸对肺癌骨转移疼痛患者的疗效-成本费用。方法:选取2013年6月—2016年6月期间于治疗的肺癌骨转移患者80例,按照用药的不同将其分为治疗组40例和对照组40例;治疗组患者给予唑来膦酸治疗,对照组患者给予伊班膦酸治疗,比较两组患者治疗后的总有效率、成本费用和不良反应的发生率。结果:治疗组患者治疗后的总有效率为90.00%稍高于对照组为85.00%(P>0.05);两组患者用药期间不良反应的发生率均为60.00%(P>0.05);治疗组患者治疗费用为42 340.00元低于对照组为59 495.00元(P<0.05)。结论:伊班膦酸与唑来膦酸在疗效和不良反应的发生率均较为接近,但唑来膦酸成本更低,药物经济学价值更高。
OBJECTIVE: To compare the efficacy of zoledronic acid and ibandronic acid in patients with bone metastases of lung cancer - costs. Methods: Totally 80 patients with lung cancer with bone metastasis were selected from June 2013 to June 2016. They were divided into treatment group (40 cases) and control group (40 cases) according to different medication. Patients in the treatment group were treated with zoledronic acid , The control group of patients given ibandronic acid treatment, the two groups were compared after the total efficiency, cost and incidence of adverse reactions. Results: The total effective rate of treatment group was 90.00%, slightly higher than that of control group (85.00%) (P> 0.05). The incidence of adverse reactions in both groups was 60.00% (P> 0.05) Patient treatment costs 42 340.00 yuan lower than the control group for 59 495.00 yuan (P <0.05). CONCLUSION: The incidence rates of ibandronate and zoledronic acid are similar both in efficacy and adverse reactions, but the cost of zoledronic acid is lower and the value of pharmacoeconomics is higher.